Lunan Pharma Rivaroxaban Tablet (Specification: 15mg) has been Approved for Listing
New Media Department Yu Jie, Duan Yuqing April 2, 2021
Rivaroxaban Tablet (Specification: 15mg) produced by Shandong New Time Pharmaceutical Co., LTD, a subsidiary company of Lunan Pharma, has been approved for listing (National Drug Standard:H20203051) by National Medical Products Administration(NMPA), and the raw material of Rivaroxaban (Registration number: Y20190000588) status changed from "I" to "A".
Rivaroxaban is the world's first direct, highly selective and competitive factor Xa inhibitor. Direct inhibition of factor Xa can interrupt the endogenous and exogenous pathways of coagulation waterfall and inhibit the production of thrombin and thrombosis. Clinical use of Rivaroxaban in adult patients undergoing elective hip or knee replacement to prevent venous thrombosis (VTE) and pulmonary embolism (PE); For the treatment of deep vein thrombosis (DVT) in adults to reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT; Use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors to reduce the risk of stroke and systemic embolism.
The main clinical advantages of Rivaroxaban include: 1. Rapid onset, fixed dose, no need for routine blood coagulation monitoring, simple administration route and improved compliance; 2. Not affected by age, gender, weight and food, relatively small side effects; 3. High bioavailability in vivo, strong anticoagulant effect, small interaction with other drugs, high safety; 4. The treatment window is wide, without rebound and offset effect, and preoperative bridging anticoagulation is not required. In conclusion, Rivaroxaban has reliable efficacy and can play a stable anticoagulant and antithrombotic effect, and reduce the risk of vascular reembolism.
With the principle of “Innovation leads, service promotes”, Lunan Pharma will actively develop new products, strive to provide patients with more high-quality and inexpensive drugs, and strive unremittingly to achieve the grand goal of "100 billion Lunan, a hundred-year brand ".